抗VEGF [EP1176Y], C-term抗体 | Anti-VEGF [EP1176Y], C-term antibody

• 特長
• 価格
• DATA IMAGES
• 製品情報
• APPLICATION
• PROPERTIES
• TARGET
• REFERENCEE(抜粋)

特長

• 高品質の抗体です。
• 幅広い研究分野に関連する抗体を取り揃えています。
• 使用されたアプリケーションや動物種などの情報が充実しています。
• 多数の論文で使用実績がある信頼性の高い抗体です。

目次に戻る

価格

目次に戻る

DATA IMAGES

	C. Immunofluorescent staining of HUVEC cells using anti-VEGF RabMAb (cat. #GTX61510).
	B. Immunohistochemical staining of hemangioma using anti-VEGF RabMAb (cat. #GTX61510).

目次に戻る

製品情報

Host	Rabbit
Clonality	Monoclonal
Clone Name	EP1176Y
Isotype	IgG
Application	ICC/IF, IHC-P, FACS, IP
Reactivity	Human, Mouse

目次に戻る

APPLICATION

Application Note

Recommended Starting Dilutions:
For IHC-P: Use at an assay dependent concentration.
For ICC/IF: 1/250 - 1/500.
For Flow Cyt: 1/100.
For IP: 1/50.
Optimal working dilution for a specific application should be determined by the investigator.

目次に戻る

PROPERTIES

Form	Liquid
Buffer	PBS containing 50% Glycerol, 0.05% BSA and 0.01% Sodium azide.
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Antigen Species	Human
Immunogen	A synthetic peptide corresponding to residues on the C-terminus of human VEGF was used as an immunogen.
Purification	Tissue culture supernatant
Conjugation	Unconjugated
Note	For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,488.

目次に戻る

TARGET

Synonyms

VEGFA, VPF, MVCD1, MGC70609, VEGF

Background

Vascular endothelial growth factor (VEGF) was recently identified as a secreted, direct-acting mitogen specific for vascular endothelial cells and capable of stimulating angiogenesis in vivo. Molecular cloning revealed multiple forms of VEGF, apparently arising from alternative splicing of its RNA transcript . VEGF and TGF-beta1 are potent angiogenesis inducers with opposing effects on endothelial cells. TGF-beta1 induces apoptosis; VEGF protects endothelial cells from apoptosis. We found that TGF-beta1 promotes endothelial cell expression of FGF-2, which up-regulates VEGF synthesis. Inhibition of VEGF signaling through VEGF receptor 2 (flk-1) abrogates TGF-beta1-induced apoptosis and p38(MAPK) activation. This finding illustrates an unexpected role of VEGF and indicates that VEGF can be pharmacologically converted into an apoptotic factor, a novel approach to antiangiogenesis therapy .

目次に戻る

REFERENCEE(抜粋)

Application Reference	Application/Reactivity
Scherbakov AM et al. Bull Exp Biol Med 2016; 160 (6) : 802-6 Regulatory Proteins of Epithelial-Mesenchymal Transition and Some Components of VEGF Signaling Pathway in Breast Cancer.	Application : IHC-P Reactivity : Human

目次に戻る